Citation Impact
Citing Papers
Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation
2020
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
2005 Standout
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Use of a Refined Drug Tracer Algorithm to Estimate Prevalence and Incidence of Parkinson's Disease in a Large Israeli Population
2011
Plasma β-amyloid in Alzheimer’s disease and vascular disease
2016 StandoutNobel
Cochrane Database of Systematic Reviews
2003 Standout
Noticing pesticide spray drift from agricultural pesticide application areas and breast cancer: a case‐control study
2013
Astrocytes: biology and pathology
2009 Standout
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
2009 Standout
Progression of parkinsonism in multiple system atrophy
2005
Prevalence of Parkinson’s disease across North America
2018
Inflammation and Alzheimer's disease
2000 Standout
Non-motor symptoms of Parkinson's disease: diagnosis and management
2006 Standout
DARPP-32 knockout mice exhibit impaired reversal learning in a discriminated operant task
2000 StandoutNobel
Parkinson disease
2017 Standout
Parkinson's disease
2021 Standout
Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography
1997
Gastrointestinal dysfunction in Parkinson's disease
2003 Standout
Syndemics and the biosocial conception of health
2017 Standout
Interactions between the microbiota, immune and nervous systems in health and disease
2017 Standout
Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages
2010
Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome
2013
The neural control of micturition
2008 Standout
Cellular metabolic and autophagic pathways: Traffic control by redox signaling
2013
Drugs Used to Treat Spasticity
2000
Systemic toxicity of botulinum toxin by intramuscular injection in the monkey
1988
Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease
2003
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
2007 Standout
The musician's brain as a model of neuroplasticity
2002 Standout
The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years
1999
Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: Protective effect by estradiol treatment in ovariectomized animals
2005
Rate of clinical progression in Parkinson's disease. A prospective study
2007
The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease
2017 Standout
Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders
2008
Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease
2007
Parkinson's disease: clinical features and diagnosis
2008 Standout
Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study
2007
Staging of brain pathology related to sporadic Parkinson’s disease
2002 Standout
Botulinum Toxin as a Biological Weapon
2001 Standout
The Relationship of Parkinson Disease With Aging
2007
Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot study
2002
Dietary Antioxidants and Parkinson Disease
1997
[sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
1996
Differences in somatosensory hand organization in a healthy flutist and a flutist with focal hand dystonia
2000
Epidemiology of Parkinson's disease
2006 Standout
Muscle releases to improve passive motion and relieve pain in patients with spastic hemiplegia and elbow flexion contractures
2012
Socioeconomic variations in the prevalence and incidence of Parkinson's disease: a population-based analysis
2009
Therapeutic Uses of Botulinum Toxin
1991
Epidemiology of Parkinsonʼs disease and akinetic syndromes
2000
Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease
2005
Parkinson's disease
2009 Standout
Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial
2007
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
The association between infectious burden and Parkinson's disease: A case-control study
2015
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease
2007
Mediation of cell death by poly(ADP-ribose) polymerase-1
2005
Glutamate neurotoxicity and diseases of the nervous system
1988 Standout
Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions
1994
Exposure to pesticides and the associated human health effects
2016 Standout
Poly-ADP-ribosylation in health and disease
2005
Functional Decline in Parkinson Disease
2001
The Relevance of Iron in the Pathogenesis of Parkinson's Disease
2004
Parkinson's disease
2015 Standout
Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases
2002
Striatal β-Amyloid Deposition in Parkinson Disease With Dementia
2008
‘Lewy body disease’: clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia
1995
Botulinum Toxin Type A as a Migraine Preventive Treatment
2000
Patterns of levodopa response in Parkinson's disease: a clinico-pathological study
2007
Deep brain stimulation for Parkinsonʼs disease and other movement disorders
2013
Poly(ADP-ribose): novel functions for an old molecule
2006 Standout
Behavioral and neurochemical characterization of α2A-adrenergic receptor knockout mice
2002 StandoutNobel
Pathology and new players in the pathogenesis of brain edema
2009
Double‐blind, placebo‐controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism
2003
Physiology of Local Renin-Angiotensin Systems
2006 Standout
Parkinson's Disease
1998 Standout
Plantation Work and Risk of Parkinson Disease in a Population-Based Longitudinal Study
2002
Transmembrane Signalling Systems in the Brain of Patients with Parkinson's Disease
1993
Non-motor features of Parkinson disease
2017 Standout
Visual symptoms in Parkinson's disease and Parkinson's disease dementia
2011
Gastrointestinal dysfunction in Parkinson's disease
2015
Longitudinal evaluation of economic and physical impact of Parkinson's disease
2001
Contributions of Positron Emission Tomography to elucidating the pathogenesis of Idiopathic Parkinsonism and Dopa Responsive Dystonia
1997
Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human
1997
Genetics of Parkinsonʼs disease
2005
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors
2009 Standout
Utility and implications of exome sequencing in early‐onset Parkinson's disease
2018
Further Assessment to Determine the Additive Effect of Botulinum Toxin Type A on an Upper Extremity Exercise Program to Enhance Function Among Individuals With Chronic Stroke but Extensor Capability
2011
Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
1997
Dementia associated with Parkinson's disease
2003
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Drooling in Parkinson's disease: A review
2014
Sleepiness and unintended sleep in Parkinson’s disease
2003
Botulinum toxin B reduces sialorrhea in parkinsonism
2003
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa
2014
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
1995 Standout
Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
2015
Residual spinothalamic tract pathways predict development of central pain after spinal cord injury
2008
Associations of welding and manganese exposure with Parkinson disease
2012
Searching for a relationship between manganese and welding and Parkinson’s disease
2005
European Experience of 200 Cases Treated with Botulinum-A Toxin Injections into the Detrusor Muscle for Urinary Incontinence due to Neurogenic Detrusor Overactivity
2003
Epidemiology of Parkinson's disease
2007
Copper Active Sites in Biology
2014 Standout
Diagnosis and Treatment of Parkinson Disease
2020 Standout
Salivary gland application of botulinum toxin for the treatment of sialorrhea.
2007
Practice parameter: Management of dementia (an evidence-based review) [RETIRED]
2001 Standout
A randomized trial of botulinum toxin A for treatment of drooling
2003
Association of Parkinson’s Disease and Its Subtypes with Agricultural Pesticide Exposures in Men: A Case–Control Study in France
2015
A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease
2004
Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease
1998
Neuropathic Pain: From Mechanisms to Treatment
2020 Standout
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
2012 Standout
Aquaporin‐4 facilitates reabsorption of excess fluid in vasogenic brain edema
2004
Guidelines for Adult Stroke Rehabilitation and Recovery
2016 Standout
The effect of L‐leucine on the absorption of levodopa, studied by regional jejunal perfusion in man.
1993
Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal
2014 Standout
Cannabinoids for Medical Use
2015 Standout
Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin
2001
The two faces of Eve
2004
Second consensus statement on the diagnosis of multiple system atrophy
2008 Standout
Inhibition of glycolysis attenuates 4-hydroxynonenal-dependent autophagy and exacerbates apoptosis in differentiated SH-SY5Y neuroblastoma cells
2013
Neurotoxins Affecting Neuroexocytosis
2000 Standout
Anti-spasticity agents for multiple sclerosis
2003
Complications in Patients with Palmar Hyperhidrosis Treated with Transthoracic Endoscopic Sympathectomy
1997 Standout
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
2006 Standout
Metals in Neurobiology: Probing Their Chemistry and Biology with Molecular Imaging
2008 Standout
Works of Joseph Tsui being referenced
Treatment of spasticity with botulinum toxin: A double‐blind study
1990
The effect of dietary protein on the efficacy of L‐dopa
1989
Daytime somnolence in patients with Parkinson's disease
2001
The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology
2003
Regulation of aquaporin-4 in a traumatic brain injury model in rats
2003
Association of Parkinson's disease with infections and occupational exposure to possible vectors
2012
Botulinum toxin as a therapeutic agent
1996
Clinical observations on the rate of progression of idiopathic parkinsonism
1994
Pesticide exposure and risk of Parkinson’s disease – a population-based case–control study evaluating the potential for recall bias
2011
Cerebral Glucose Metabolism in Parkinson's Disease With and Without Dementia
1992
The long-term response to levodopa in dopa-responsive dystonia
2001
The Canadian multicentre study of deep brain stimulation for cervical dystonia
2007
Angiotensin regulates endothelin-B receptor in rat inner medullary collecting duct
2001
Occupational and environmental risk factors for Parkinson's disease
2002
Clustering of Parkinson Disease
2004
A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis
1985
Botulinum toxin type B in the treatment of cervical dystonia
1995
A double‐blind, placebo‐controlled, dose‐ranging study to investigate the safety and efficacy of CY 208‐243 in patients with Parkinson's disease
1989
Occupational Risk Factors in Parkinson’s Disease
1999
Botulinum toxin A as treatment for drooling saliva in PD
2000
DNAJC13 genetic variants in parkinsonism
2014
Botulinum toxin in the treatment of writer's cramp
1993